AbbVie’s immunology portfolio registered global net revenues of $5.58bn during Q1 2023. Credit: © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A.

AbbVie has reported global net revenues of $12.23bn for the first quarter (Q1) of 2023, representing a decline of 9.7% on a reported basis and 8.3% on an operational basis from Q1 2022.

During Q1 2023, net revenues from the company’s immunology portfolio fell to $5.59bn, down by 9% on a reported basis and 7.8% on an operational basis.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Global net revenues from the drug Humira were $3.54bn, a 25.2% decline on a reported basis, or 24.3% on an operational basis, from the same quarter of the previous year.

The drug generated net revenues of $2.95bn in the US, a drop of 26.1% year-on-year.

AbbVie has reported global net revenues of $1.36bn from Skyrizi and $686m from Rinvoq. The net revenue growth on a reported basis was 44.7% for Skyrizi and 47.5% for Rinvoq.

The haematologic oncology portfolio delivered $1.42bn in global net revenues during the quarter, down by 14% year-on-year on a reported basis.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company’s neuroscience portfolio witnessed a growth of 13.9% on a reported basis over Q1 2022, registering net revenues of $1.7bn.   

Net revenues from the aesthetics portfolio fell by 5.4% to $1.3bn, compared to the same period last year.

AbbVie chairman and CEO Richard Gonzalez stated: “This year is off to an excellent start, with first-quarter revenues and EPS ahead of our expectations, driven by strong commercial execution across all areas of our diversified portfolio.

“These balanced results give us confidence to increase our full-year guidance and we see numerous opportunities for key assets to drive compelling long-term growth.”

For the full year 2023, the company has increased its adjusted diluted earnings per share (EPS) guidance range from between $10.62 and $11.02 to between $10.72 and $11.12.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact